---
title: 'Long-term outcomes of a cultured autologous dermo-epidermal skin substitute
  in children: 5 year results of a phase I clinical trial'
date: '2024-08-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39115183/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240808182348&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Limited donor sites and poor long-term outcomes with standard treatment
  for large skin defects remain a huge problem. An autologous, bilayered, laboratory-grown
  skin substitute (denovoSkin™) was developed to overcome this problem and has shown
  to be safe in ten pediatric patients in a phase I clinical trial after transplantation.
  The goal of this article is to report on 48 months long-term results. The pediatric
  participants of the phase I clinical trial were followed at yearly visits up to
  ...
disable_comments: true
---
Limited donor sites and poor long-term outcomes with standard treatment for large skin defects remain a huge problem. An autologous, bilayered, laboratory-grown skin substitute (denovoSkin™) was developed to overcome this problem and has shown to be safe in ten pediatric patients in a phase I clinical trial after transplantation. The goal of this article is to report on 48 months long-term results. The pediatric participants of the phase I clinical trial were followed at yearly visits up to ...